ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Zinc Fingers as Programmable Metalloprotein Scaffolds for Altering Pathogenic Biomolecular Phase Transitions.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Tunable control over biomolecular phase transitions provides a powerful blueprint for engineering functional soft materials, yet generalizable protein scaffolds capable of rewiring pathological condensates remain largely unexplored. Here, we demonstrate that zinc finger (ZF) proteins function as programmable interaction units that modulate neurodegenerative amyloid liquid-liquid phase separation, redirect β-sheet-rich fibrillation toward nontoxic assemblies, and actively disassemble preformed fibrils. Multiscale investigations spanning molecular, cellular, and organismal levels reveal that tandemly arrayed ZF modules mediate direct, high-affinity protein-protein interactions, thereby mitigating amyloid pathogenicity. Through modular protein engineering, these protective effects translate in vivo, where a brain-penetrant ZF variant reduces amyloid deposition, suppresses neuroinflammatory responses, and improves cognitive performance in Alzheimer's disease transgenic mice. Furthermore, sequence-structure-function analyses identify key determinants governing amyloid assembly control, offering mechanistic principles for ZF-inspired protein engineering. Collectively, this work positions ZF proteins as versatile, chemically programmable platforms for engineering protein-based materials that regulate biomolecular phase behavior and toxicity, expanding their functional scope beyond traditional genetic regulation toward therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.